-- Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that ... Scottrade, 3 days ago
Acucela Inc.???s Emixustat Hydrochloride, in Development For Geographic Atrophy Associated With Dry Age-Related Macular Degeneration, Subject Of Podium Presentation At The American Academy of Ophthalmology 2014 Annual Meeting - BioSpace, 2 days ago
Acucela's Emixustat Hydrochloride in Development for Geographic Atrophy Associated with Dry Age-Related Macular Degeneration Subject of Podium Presentation at the American Academy of Ophthalmology 2014 Annual Meeting - PharmiWeb, 3 days ago
on your WebpageAdd Widget >Get your members hooked!